Our Story

Faraday’s innovative approach to medicine stems from our beginnings

We are a clinical-stage biopharmaceutical company founded by Dr. Mark Roth of the Fred Hutchinson Cancer Center in Seattle and backed by an investor group led by ARCH Venture Partners and Polaris Partners.

FARADAY

Dedicated to living longer, better

OUR FOCUS: protecting the quality of life for patients experiencing a potentially life changing critical illness

By developing drugs to prevent and treat cardiac and skeletal muscle loss, we hope to improve clinical outcomes associated with various acute conditions, including myocardial infarction.

An image of a red heart in the chest of a patient (xray) — **FDY-5301:**

**The first step in solving the reperfusion problem**

Our lead compound,
FDY-5301, is a formulation of sodium iodide designed to reduce ischemia-reperfusion injury (IRI)

a phenomenon that occurs during revascularization of an ischemic tissue. Although restoring blood flow is necessary, the process of tissue reoxygenation paradoxically creates more tissue damage due to reactive oxygen species production and inflammation. In the case of a heart attack from an occluded coronary artery, IRI leads to increased infarct size, which may increase the risk of cardiovascular death or heart failure.

There is currently no approved therapeutic agent to limit IRI

FDY-5301 reduced tissue damage, infarct size, and inflammation in preclinical models of IRI and was studied in a Phase 2 clinical trial with encouraging results

Anterior STEMI typically represents an acute occlusion of the most vital coronary artery, the left anterior descending, and its reperfusion by PCI is believed to have the most IRI-mediated damage among heart attacks as well as risk of subsequent heart failure. A Phase 3 trial of FDY-5301 is now underway in anterior STEMI patients, representing an opportunity to be a first-in-class intervention for reducing cardiovascular mortality and heart failure.

FDY-5301

NEWS